BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
Find more results for BCRX
12.25
+0.51 (4.34%)
After Hours: 12.25 0.00 (0.00%)
Jul 29, 6:05PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.62 - 12.27
52 week 3.67 - 13.33
Open 11.76
Vol / Avg. 0.00/1.31M
Mkt cap 876.79M
P/E     -
Div/yield     -
EPS -0.63
Shares 71.57M
Beta 2.77
Inst. own 72%
Aug 5, 2014
Q2 2014 BioCryst Pharmaceuticals Inc Earnings Call - 11:00AM EDT - Add to calendar
Aug 5, 2014
Q2 2014 BioCryst Pharmaceuticals Earnings Release - 9:30AM EDT - Add to calendar
Jun 24, 2014
BioCryst Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 17, 2014
BioCryst Pharmaceuticals Inc at Wells Fargo Healthcare Conference
May 27, 2014
BioCryst Conference Call to Announce Results From the BCX4161 OPuS-1 Phase 2 Trial for Hereditary Angioedema
May 13, 2014
BioCryst Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Q1 2014 BioCryst Pharmaceuticals Earnings Conference Call
May 8, 2014
Q1 2014 BioCryst Pharmaceuticals Earnings Release
May 2, 2014
BioCryst Pharmaceuticals Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -293.15% -173.72%
Operating margin -213.59% -177.24%
EBITD margin - -175.48%
Return on average assets -88.15% -56.64%
Return on average equity - -
Employees 40 -
CDP Score - -

Address

2190 PARKWAY LAKE DR
BIRMINGHAM, AL 35244
United States - Map
+1-205-4444600 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company's pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Vice President - Drug Discovery
Age: 61
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Director
Age: 57
Bio & Compensation  - Reuters
Stanley C. Erck Independent Director
Age: 66
Bio & Compensation  - Reuters
Nancy J. Hutson Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters